Two-year Results of Preserflo Microshunt use in Open-angle Glaucoma Surgery

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001475" target="_blank" >RIV/00064190:_____/25:10001475 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.31348/2025/9" target="_blank" >https://doi.org/10.31348/2025/9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.31348/2025/9" target="_blank" >10.31348/2025/9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Two-year Results of Preserflo Microshunt use in Open-angle Glaucoma Surgery

Popis výsledku v původním jazyce

Aim: To evaluate the safety and efficacy outcomes of PRESERFLOTM MicroShunt implantation in patients with primary open-angle glaucoma. Material and Methods: Retrospective data analysis of 19 eyes of 12 patients, comprising 5 females and 7 males. The patients underwent surgery between August 2020 and February 2022. The follow-up period was 24 months after surgery. During the follow-up period, intraocular pressure (IOP), the need to apply topical antiglaucoma medication and its spectrum, visual field status, optic nerve target findings and postoperative complications were recorded. The indication for PRESERFLOTM MicroShunt implantation was primary open angle glaucoma (POAG), poorly controlled with maximum tolerated medical therapy. Results: Average IOP was reduced from 19.05 +-5.58 mmHg preoperatively to 11.47 +-2.48 mmHg at 3 months postoperatively, 12.26 +-2.48 mmHg at 6 months postoperatively, 14.0 +-2.43 mmHg at 12 months postoperatively, 11.78 +-2.37 mmHg at 18 months postoperatively, and 12.73 +-2.51 mmHg at 24 months postoperatively (p &lt; 0.001). No antiglaucoma medication was required in 19 eyes 3 months after surgery, in 19 eyes 6 months after surgery, 19 eyes 12 months after surgery, 16 eyes 18 months after surgery and 15 eyes 24 months after surgery. One eye (5.26%) required monotherapy 18 months after surgery, and 2 eyes (10.52%) 24 months after surgery. Dual combination therapy was required 18 months after surgery in 2 eyes (10.52%) and 24 months after surgery in 2 eyes (10.52%). In the early postoperative period we found a loose conjunctival suture in 3 eyes, which was followed by resuturing in 1 eye. In the late postoperative period we found an obturated implant in 1 eye, which required implant replacement. Conclusion: Our initial results suggest that the PRESERFLOTM MicroShunt glaucoma implant is an effective surgical technique with minimal postoperative complications, resulting in a statistically significant reduction in average IOP and discontinuation or reduction of topical antiglaucoma medication for 2 years after surgery. (C) 2025, Czech Medical Association J.E. Purkyne. All rights reserved.

Název v anglickém jazyce

Two-year Results of Preserflo Microshunt use in Open-angle Glaucoma Surgery

Popis výsledku anglicky

Aim: To evaluate the safety and efficacy outcomes of PRESERFLOTM MicroShunt implantation in patients with primary open-angle glaucoma. Material and Methods: Retrospective data analysis of 19 eyes of 12 patients, comprising 5 females and 7 males. The patients underwent surgery between August 2020 and February 2022. The follow-up period was 24 months after surgery. During the follow-up period, intraocular pressure (IOP), the need to apply topical antiglaucoma medication and its spectrum, visual field status, optic nerve target findings and postoperative complications were recorded. The indication for PRESERFLOTM MicroShunt implantation was primary open angle glaucoma (POAG), poorly controlled with maximum tolerated medical therapy. Results: Average IOP was reduced from 19.05 +-5.58 mmHg preoperatively to 11.47 +-2.48 mmHg at 3 months postoperatively, 12.26 +-2.48 mmHg at 6 months postoperatively, 14.0 +-2.43 mmHg at 12 months postoperatively, 11.78 +-2.37 mmHg at 18 months postoperatively, and 12.73 +-2.51 mmHg at 24 months postoperatively (p &lt; 0.001). No antiglaucoma medication was required in 19 eyes 3 months after surgery, in 19 eyes 6 months after surgery, 19 eyes 12 months after surgery, 16 eyes 18 months after surgery and 15 eyes 24 months after surgery. One eye (5.26%) required monotherapy 18 months after surgery, and 2 eyes (10.52%) 24 months after surgery. Dual combination therapy was required 18 months after surgery in 2 eyes (10.52%) and 24 months after surgery in 2 eyes (10.52%). In the early postoperative period we found a loose conjunctival suture in 3 eyes, which was followed by resuturing in 1 eye. In the late postoperative period we found an obturated implant in 1 eye, which required implant replacement. Conclusion: Our initial results suggest that the PRESERFLOTM MicroShunt glaucoma implant is an effective surgical technique with minimal postoperative complications, resulting in a statistically significant reduction in average IOP and discontinuation or reduction of topical antiglaucoma medication for 2 years after surgery. (C) 2025, Czech Medical Association J.E. Purkyne. All rights reserved.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30207 - Ophthalmology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Česká a Slovenská Oftalmologie

ISSN

1211-9059

e-ISSN

—

Svazek periodika

81

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

8

Strana od-do

189-196

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-105019666201